Recall Enforment Report D-0028-2026

Recall Details

Drug Recall Enforcement Report Class II voluntary initiated by ASTRAZENECA PHARMACEUTICALS, originally initiated on 10-08-2025 for the product Fasenra (benralizumab) Injection, 30 mg/mL, one single-dose pre-filled syringe, Rx only, Manufactured by: AstraZeneca AB, Sweden, Distributed by: AstraZeneca Pharmaceuticals LP, Wilmington, DE 19850. NDC 0310-1730-30 The product was recalled due to lack of assurance of sterility:. The product was distributed nationwide and the recall is currently ongoing.

Field Name Field Value
Event ID 97760 What is the Event ID?
A numerical designation assigned by FDA to a specific recall event (used for tracking purposes).
Recall Number D-0028-2026 What is the Recall Number?
An alphanumeric designation assigned by FDA to a specific, classified recalled product (used for tracking purposes).
Recall Classification Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote What is the Recall Classification?
Numerical designation (I, II, or III) that is assigned by FDA to a particular product recall that indicates the relative degree of health hazard. For recalls pending classification, the entry will display as "Not Yet Classified".
Distribution Pattern Nationwide in the U.S What is the Distribution Pattern?
General area of initial distribution such as states, countries, or territories. Note that subsequent distribution by the consignees to other parties may not be included.
Product Description Fasenra (benralizumab) Injection, 30 mg/mL, one single-dose pre-filled syringe, Rx only, Manufactured by: AstraZeneca AB, Sweden, Distributed by: AstraZeneca Pharmaceuticals LP, Wilmington, DE 19850. NDC 0310-1730-30
Reason For Recall Lack of Assurance of Sterility: What is the Reason for Recall?
Information describing how the product is defective.
Product Quantity 916 pre-filled syringes Product Quantity
The amount of product subject to recall.
Voluntary Mandated Voluntary: Firm initiated Voluntary / Mandated
Designates that a recall was initiated voluntarily by a firm on its own volition or after being requested to recall by FDA. “Mandatory” designates that a recall was initiated under a mandatory (statutory) recall authority, a court order, or FDA order.
Report Date 10-22-2025
Recall Initiation Date 10-08-2025 What is the Recall Initiation Date?
The date that the firm first began notifying the public or their consignees of the recall.
Initial Firm Notification E-Mail Initial Firm Notification of Consignee or Public
The method(s) by which the firm initially notified the public or their consignees of a recall.
Product Type Drugs
Recalling Firm ASTRAZENECA PHARMACEUTICALS
Code Info Lot YJ0152, Expiry: 01/31/2028. Code Information
A list of all lot and/or serial numbers, product numbers, expiration dates, sell or use by dates, etc., which appear on the product or its labeling.
Recalled NDC Packages 0310-1730-30; 0310-1730-85; 0310-1830-30; 0310-1830-85; 0310-1745-01; 0310-1745-95
Status Ongoing

Recalled Products

NDC Proprietary Name Non-Proprietary Name Dosage Form Route Name Company Name Product Type
0310-1730Fasenra BenralizumabInjection, SolutionSubcutaneousAstrazeneca Pharmaceuticals LpHuman Prescription Drug
0310-1745Fasenra BenralizumabInjection, SolutionSubcutaneousAstrazeneca Pharmaceuticals LpHuman Prescription Drug
0310-1830Fasenra BenralizumabInjection, SolutionSubcutaneousAstrazeneca Pharmaceuticals LpHuman Prescription Drug